Background Venous thromboembolism is a common, potentially avoidable cause of death and morbidity in patients in hospital, including those with stroke. In surgical patients, intermittent pneumatic compression (IPC) reduces the risk of deep vein thrombosis (DVT), but no reliable evidence exists about its eff ectiveness in patients who have had a stroke. We assessed the eff ectiveness of IPC to reduce the risk of DVT in patients who have had a stroke.
Introduction
Venous thromboembolism is one of the most important, potentially preventable, causes of death and morbidity in patients in hospital. 1 Although its importance has long been recognised in patients undergoing surgery, it is now clear that medical patients (sometimes referred to as non-surgical patients) also have a high risk of venous thromboembolism. Patients who have had a stroke are at especially high risk; in prospective studies, venous thrombo embolism has been detected in 20-42% of patients in hospital who have had a stroke. [2] [3] [4] Most healthcare systems in developed countries have established guidelines promoting routine assessments of risk of venous thromboembolism on hospital admission and the initiation of prophylaxis in high-risk patients. [5] [6] [7] Prophylaxis with antithrombotic drugs or physical methods, such as intermittent pneumatic compression (IPC), reduces the risks of deep vein thrombosis (DVT) in patients undergoing surgery; but the balance of risk and benefi t for these approaches in medical patients is more contentious. 5, 8, 9 After stroke, graduated compression stockings are not eff ective, and the guideline-recom mended strategy of selective use of anticoagulants in patients at high risk of venous thromboembolism and low risk of bleeding is impossible to achieve in practice because of the overlap of the factors that predict venous thromboembolism and those pre dicting bleeding risk.
IPC includes infl atable sleeves that are wrapped around the legs and secured by Velcro (fi gure 1). The sleeves can be applied to the calf alone, or the calf and thigh. They are infl ated, one side at a time, to compress the legs at intervals. Some types infl ate sequentially, fi rst distally, then proximally to increase venous fl ow. The frequency of infl ation can be fi xed, or in more sophisticated systems can be varied depending on the rate of venous refi ll. IPC is thought to reduce the risk of venous thrombosis by reducing stasis and stimulating release of intrinsic fi brinolytic factors. 11 IPC has mainly been assessed in patients during, and immediately after, surgical operations. A systematic review 12 identifi ed 22 randomised trials of IPC, which included a total of 2779 patients. Use of IPC was associated with a 64% reduction in the odds of DVT (proximal or calf; p<0·0001). 12 This review 12 concluded that a priority for future research was trials of "prevention of venous thromboembolism with mechanical methods among high-risk medical patients (such as those with stroke)". A Cochrane review 13 of trials of IPC after stroke identifi ed only two trials including 177 patients in total, 13 showing IPC was associated with a non-signifi cant reduction in risk of DVTs (OR 0•45, 95% CI 0•19-1•10).
The CLOTS 3 trial therefore aimed to establish whether the routine application of IPC to the legs of immobile patients who had had a stroke reduced their risk of DVT.
Methods

Study design and participants
CLOTS 3 trial is a multicentre, parallel group trial that took place in 105 hospitals in the UK. The protocol and statistical analysis plan have been published previously. 14, 15 The full protocol can be viewed online.
To be included in the trial, patients had to be admitted to hospital within 3 days of acute stroke and be immobile (ie, could not mobilise to the toilet without the help of another person). Exclusion criteria included age lower than 16 years, subarachnoid haemorrhage, or contraindications to IPC such as dermatitis, leg ulcers, severe oedema, severe peripheral vascular disease, and congestive cardiac failure.
Patients or a proxy provided written informed consent. 
Randomisation and masking
On the day of admission (day 0) or up to day 3, patients were randomly assigned (ratio 1:1) to either receive IPC or not receive it. The clinician entered the patient's baseline data via a web-based or a 24-h telephone randomisation service. After checking the data for completeness and consistency, the system generated a treatment allocation. We used a minimisation algorithm to achieve optimum balance for the following factors: delay since stroke onset (day 0 or 1 vs day ≥2 days); stroke severity calculated with a validated prognostic model; 16 leg weakness (able or not to lift both legs off the bed); receiving heparin or warfarin at enrolment or had received thrombolysis since the stroke. Simple minimisation can theoretically lead to alternation of treatment allocation, which in this open treatment trial, might lead to fore-knowledge of the next treatment to be assigned. So, to ensure allocation concealment, our system also incorporated a degree of random allocationie, it allocated patients to the treatment group that minimised the diff erence between the groups with a probability of 0•8 rather than 1•0. 17 All patients and investigators were aware of treatment allocation, the radiologist or technician doing the CDU were masked to treatment group.
Procedures
For patients allocated to the IPC group, we applied the Kendall SCD TM express sequential compression system (Covidien, MA, USA; fi gure 1), according to the manufacturer's instructions, to both legs. We used thigh-length sleeves. This system delivers sequential circum ferential compression and incorporates venous refi ll technology so that the frequency of compression is tailored to the individual patient. We aimed to apply IPC continuously, both day and night, (except during washing, physiotherapy, or screening compression duplex ultrasound [CDUs]) for a minimum of 30 days from randomisation, or until a second screening CDU had been done (if after 30 days). IPC was discontinued early if the patient: became independently mobile, was discharged from the participating hospital, declined to continue IPC, had adverse eff ects of the IPC that warranted removal. To enhance adherence, the manufacturer introduced a modifi ed IPC sleeve, the Kendall SCD TM sequential compression "Comfort" sleeves. We switched to this new sleeve for the 1197 (42%) patients Nursing staff recorded the application of IPC on the medication chart every day to aid adherence monitoring. We defi ned perfect adherence (ie, 100% adherence) as wearing IPC from randomisation until the patient regained mobility, was discharged from a participating hospital, died, or until 30 days or until a delayed second screening CDU. We asked that clinicians should not take the patient's treatment allocation into account when deciding whether or not to use antithrombotic drugs after enrolment, to ensure that, as far as possible, both treatment groups received the same background thromboprophylactic care.
For the follow-up, we aimed to do a CDU between days 7 and 10 and, wherever practical, between days 25 and 30 after randomisation, even if the patient had been discharged from hospital. The plan not to do the second CDU was captured securely before randomisation, which might be the case if the patient was likely to be discharged home to another region or transferred to a rehabilitation facility that did not have facilities to do a CDU, and was remote from the randomising centre. We allowed researchers to plan not to do a second CDU to minimise bias that might arise because of unplanned failures to complete a second CDU. We stipulated that; the IPC should be removed before the CDU, to mask the radiologist or technician to the treatment group; the technician should be performing CDU regularly as part of a clinical service and the CDU should cover at least the popliteal and femoral veins in both legs (ie, visualisation of calf veins was not mandatory). The technician completed a report form including: whether there was a DVT aff ecting femoral, popliteal or calf veins in each leg; whether the calf veins were fully visualised; whether the patient arrived wearing IPC. We obtained a hard copy of any scans reporting a primary outcome for central verifi cation by a radiologist (JR). In the absence of a hard copy we obtained the local clinical radiology report of the CDU.
After discharge, or death in hospital, based on a review of the medication charts and medical records, the local coordinator completed a discharge form that included the early secondary outcomes. We sent a postal questionnaire to every patient's general practitioner about 24 weeks after enrolment to establish the patient's vital status, and the occurrence of DVTs or pulmonary emboli since hospital discharge. We followed up surviving patients at 6 months after enrolment by postal questionnaire; in nonresponders, the chief investigator (MD) did a telephone interview masked to treatment allocation.
Statistical analysis
The primary outcome was a symptomatic or asymptomatic DVT in the popliteal or femoral (proximal) veins detected on a screening CDU or any symptomatic DVT in the popliteal or femoral veins, confi rmed on imaging, within 30 days of randomisation.
The secondary outcomes within 30 days were: death, any DVT (including symptomatic or asymp tomatic calf, popliteal or femoral), symptomatic DVT, pulmonary embolism confi rmed on imaging or autopsy, complications of IPC (eg, skin breaks, falls with injury, fractures) and adherence. For every patient, we expressed adherence as a percentage, which we calcu lated from the number of days the IPC was worn (ie, end date minus start date) divided by the number of days it should have been worn according to our protocol. We did not collect the number of hours per day the IPC was worn.
The secondary outcomes at 6 months were: death from any cause and any confi rmed symptomatic or asymptomatic DVT or pulmonary embolism occurring since randomisation. Other secondary outcomes measured at 6 months included: place of residence; functional status and health related quality of life and symptoms of possible post phlebitic leg syndrome (eg, leg swelling or ulcers). These data will be reported elsewhere as part of a health economic analysis.
We originally planned to enrol at least 2000 patients, although we prespecifi ed that the trial steering committee would review this in the light of the overall rate of the primary outcome in both groups combined. This aimed to give the trial more than 90% power (α 0•05 [2-sided] ) to identify an absolute reduction of risk of our primary outcome of 4% (ie, from 10% to 6%). On Nov 1, 2010, the frequency of the primary outcome in both groups combined among the 581 patients enrolled was 12•2%. The trial steering com mittee, without reference to the unblinded data therefore revised the sample size to 2800 to ensure that the trial maintained power to detect a 4% absolute diff erence in proximal DVT (ie, 14% to 10%). The frequency of the primary outcome later fell gradually but the trial steering committee decided not to reduce the sample size. The trial steering committee remained masked to any analyses split by treatment group through out the trial.
The trial statistician (CG) prepared analyses of the accumulating data, which the independent data monitoring committee reviewed in strict confi dence at least once a year. No explicit stopping rules existed. No other members of the trial team, trial steering committee, or participants had access to these analyses. Before recruitment was completed, and without input from the trial statistician or reference to the unblinded data, the trial steering committee prepared a detailed analysis plan that was then published. 15 For the purposes of all primary analyses, we retained participants in the treatment group to which they were originally assigned irrespective of the treatment they actually received. Inevitably, some patients withdrew and were lost to follow-up, and some who did return follow-up questionnaires left items blank. We excluded these patients from the analyses that they had no data for, and we did sensitivity analyses to assess the eff ect of these exclusions on the overall conclusions. For binary outcomes (eg, occurrence of a primary outcome or not), outcomes are presented as odds ratios (ORs) and 95% CIs, adjusted using logistic regression for the variables in the minimisation algorithm. We calcu lated absolute reductions in risk from these values. We used Cox proportional hazards modelling to analyse the eff ect of treatment on survival to 6 months, adjusting for the variables included in our minimisation algorithm.
The prespecifi ed subgroup analyses were: the eff ect of treatment allocation on the primary outcome subdivided by key baseline variables: delay from stroke onset to random isation (day 0 or 1 vs day 2 to 7 and day 0 to 2 vs 3-7); weakness of the legs (able to lift both legs or not); stroke severity (with a validated prognostic model); 16 risk of DVT (high vs low; based on presence or not of risk factors at baseline); 18 use of heparin, warfarin, or thrombolysis at the time of enrol ment; type of stroke (confi rmed haemorrhagic vs ischaemic stroke or unknown pathological type of stroke); type of compression sleeves used (Original vs Comfort). We did the subgroup analyses by observing the change in loglikelihood when the interaction between the treatment and the subgroup was added into a logistic regression model. We did the statistical analyses using SAS v 9.2 (SAS Institute Inc, Cary, NC, USA).
The study is registered with http://www.ControlledTrials.com, number ISRCTN93529999.
Role of the funding source
The funding organisations, including Covidien, had no role in study design, data collection, data analysis, data inter pretation, or writing of the report. The corres ponding Able to walk without help* 0 0
Stroke severity-probability of being alive and independent in daily activities=0-0·15) † 898 (62%) 892 (62%)
Stroke severity -median (IQR) probability of being alive and independent in daily activities Data are number of patients (%) unless otherwise stated. IPC=intermittent pneumatic compression. TIA=transient ischaemic attack. *Factors included in model to predict probability of being alive and independent at 6 months. 16 †Variables included in minimisation. author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Dec 8, 2008 , and Sept 6, 2012, 2876 patients were enrolled in 94 centres in the UK and an additional 11 centres took responsibility for delivering the allocated treatment and follow-up for patients who were transferred from the randomising hospital (appendix). Of the 2876 patients enrolled, 1438 were randomly assigned to receive IPC and 1438 to receive no IPC (fi gure 2). The patients' baseline characteristics were well balanced between treatment groups (table 1). Use of prophylactic dose heparin or low molecular weight (LMWH) after randomisation was very similar between treatment groups (table 2) . There was a small excess of the use of graduated compression stockings in the IPC group, perhaps because manufacturers have previously recommended using IPC and graduated compression stockings in combination.
The mean duration of IPC use was 12•5 days (SD 10•9) and the median duration was 9 days (IQR 3-22). Perfect adherence was achieved in 445 (31%) of 1438 patients in the IPC group. The mean adherence was 59•2% (SD 10•9) and the median adherence was 65•4% (IQR 20-100). Table 3 shows patients' outcomes with respect to our primary and secondary outcomes within 30 days of enrolment. The primary outcome occurred in 122 (8·5%) of 1438 patients allocated to IPC and in 174 (12·1%) of 1438 patients allocated to no IPC (table 3; OR 0·65 (95% CI 0·51-0·84; p=0•001 after adjustment for baseline variables). The absolute reduction risk (ARR) was 3•6% (95% CI 1•4-5•8%). 156 (5%) of 2876 patients attended their fi rst or second CDU wearing IPC sleeves, which meant that the technician could not be masked for their assessment. Our primary outcome was confi rmed in 276 (93%) of the 296 patients by central review of the images (reviewed by JR) and in the remaining 20 (7%) patients by the local clinical report. To allow for any observer bias in detecting symptomatic DVTs not detected on routine screening CDU, we repeated the primary analysis excluding those primary outcomes where a DVT was suspected before the CDU (n=22). The estimates of eff ect were unchanged (data not shown).
We noted signifi cant reductions in the outcome of any DVT(symptomatic or asymptomatic involving proximal or calf veins) and symptomatic DVT (including proximal or calf; table 3). Not all patients had their calf veins visualised fully, so in patients with a fi rst CDU, we are unable to exclude an isolated calf DVT in 615 (47%) of 1315 patients in the IPC group and in 596 (46%) of 1305 patients in the no-IPC group. In those with a second CDU, we are unable to exclude an isolated calf DVT in 453 (47%) of 955 patients in the IPC group and in 458 (49%) of 938 patients in the non-IPC group.
Patients allocated to IPC had signifi cantly more skin breaks than did patients allocated to no IPC but the risk of falls with injury or fractures within 30 days did not diff er between groups (table 3). Few of the skins breaks or falls with injury were attributed by the local researchers to the IPC. Most adverse events either occurred when IPC had been removed, or skin breaks aff ected the heels (which are not covered by the IPC sleeves) so were unlikely to be due to the IPC. However, the reporting of secondary outcomes in hospital and adverse eff ects was based on case-note review and was not masked to treatment allocation. These data for adverse events are therefore prone to ascertainment bias.
We noted non-signifi cantly fewer deaths from all causes within 30 days for those allocated IPC (table 3 ). The Cox model adjusted for the factors included in our minimisation algorithm showed a reduced probability of death for death up to 6 months after randomisation in those allocated IPC (fi gure 3).
We noted no evidence of an excess of venous thromboembolism events in the post treatment period to indicate that IPC simply deferred venous thromboembolism events (table 4). In our prespecifi ed subgroup analyses, we noted no signifi cant interactions in our subgroups with the eff ect of treatment on the primary outcome (fi gure 4).
Discussion
The CLOTS 3 trial has shown that IPC (delivering sequential circumferential compression via thigh-length sleeves at a frequency determined by the venous refi ll time) applied to immobile stroke patients, is safe, and reduces the risk of proximal DVT (our primary outcome), symptomatic DVTs (proximal or calf) and all DVTs (symptomatic or asymptomatic, proximal or calf signifi cant. Although we noted a signifi cant excess of skin breaks and a non-signifi cant excess of falls with injury, the absolute risks were low and most adverse events were not attributed to the IPC. Reassuringly, there was a potentially important improvement in survival. The CLOTS 3 trial included about the same number of patients as had been included in all previous randomised trials combined in medical and surgical patients of IPC identifi ed by systematic reviews (panel). 8, 12, 13 The CLOTS 3 trial focused on prevention and identifi cation of proximal DVTs, which are detected more reliably with CDU, and are considered clinically more important than DVTs restricted to the calf. Calf DVT's are the most frequent component of the cluster of venous thromboembolism events used in previous trials of venous thromboembolism prophylaxis, 8, 19 yet their detection with CDU is technically challenging and results are inconsistent. The patients in CLOTS 3 were enrolled by many hospitals in the UK, and had baseline characteristics that were similar to the 47% of unselected patients with acute stroke admitted to Scottish hospitals Fractures within 30 days 4 (0·3%) 4 (0·3%) 0·0 (-0·4 to 0·4)
All odds ratios and risk ratios are adjusted for the variables included in the minimisation algorithm, as specifi ed in the statistical analysis plan, unless otherwise stated. IPC=intermittent pneumatic compression. DVT=deep vein thrombosis.*Risk ratios were not prespecifi ed in our statistical analysis plan but are presented to enhance interpretation of results. 20 This suggests that our results have external validity and would apply to about half of all patients who had had a stroke admitted to hospital. Our pre specifi ed decision to increase our sample size to take account of the overall primary event rate ensured that the trial had adequate power (>90%) to detect a 4% absolute diff erence in risk of proximal DVT. Central randomisation, mainly masked assessment of our primary outcome, low losses to follow-up and intention-to-treat analysis have minimised bias.
The trial has some limitations: moderate adherence to IPC; imperfect masking of the technicians (because of some patients attending the CDU wearing the IPC, which could bias detection of our primary outcome); no masking of caregivers (which might bias their use of background treatment and assessment of some of the secondary outcomes); no masking of patients; some scheduled CDUs 
0·65 (0·51-0·84)
did not include the calf veins and some were missing; and, we did not systematically screen for pulmonary emboli. All of these might mean we have underestimated the frequency of venous thromboembolism. Furthermore, because we sys tematically screened for them, many patients found to have asymptomatic DVT were then treated with anticoagulants to lessen the risk of symptomatic events (DVTs, pulmonary emboli, and deaths) occurring. This might bias the estimate of the eff ect of IPC. Other potential limitations included: lack of central verifi cation of negative scans, use of selective source data verifi cation and imbalance in the background use of graduated compression stockings but we deem these are unlikely to have introduced bias or altered the external validity of the results. The search strategy used in the Cochrane review of physical methods for preventing deep vein thrombosis in stroke was updated in March 2013. 13 Only the two small randomised trials included in the original review were identifi ed. The reduction in DVT observed in CLOTS 3 is likely to be due to the reduced venous stasis and possibly the eff ects on intrinsic fi brinolysis observed with IPC. 11 The improved survival to 6 months observed in those allocated IPC is potentially of clinical signifi cance. However, the eff ect on survival was not expected, and the CLOTS 3 trial had less than 50% power to detect such an eff ect; a trial with about 8500 patients would be required to provide 90% power to detect the observed reduction in all-cause mortality. Unfortunately, the autopsy rate was very low, so we were unable reliably to assign a cause to most deaths, especially given the diffi culty of distin guishing pulmonary embolism from other cardio-respira tory problems in patients who have had a stroke. 21 Selection bias and ascertainment biases are unlikely explanations for our fi ndings since prognostic factors were balanced at baseline and losses to follow-up were extremely low. Therefore, taken with the pattern of benefi ts across all the secondary outcomes, it seems plausible that the diff erence in survival might be real and attributable, at least in part, to IPC. The most likely mechanism is a reduction in undiagnosed pulmonary embolism that contributed to death.
Previous meta-analyses of trials of heparins/LMWH in medical patients, including those with stroke (n=36 122 patients) have shown signifi cant reductions in pulmonary emboli (three in 1000, 95% CI 1-3), but only non-signifi cant reduction in deaths (six in 1000, 0-11), perhaps partly because any reduction in major venous thromboembolism was off set by a signifi cant increase in major bleeds (four in 1000, 1-7). 8, 9 By contrast, IPC was not associated with an excess of any major adverse eff ects that might off set the benefi ts. The observed eff ect of IPC on survival in CLOTS 3 is also reassuring about its safety in this high-risk vulnerable population.
CLOTS 3 provides clear evidence that IPC is eff ective in reducing the risk of both proximal, symptomatic and "any DVT" in immobile patients who have had a stroke. Our subgroup analyses suggest that the eff ect is similar across a broad range of patients. Importantly, IPC seems to be as eff ective in patients with haemorrhagic stroke (fi gure 4). Moreover, we have shown that IPC is moderately well tolerated and might even improve survival after stroke. IPC seems also likely to be eff ective in other medical groups of patients at high risk of DVT.
Panel: Research in context
Systematic review
In stroke, results from large randomised trials had shown that prophylactic heparin/low molecular weight heparin ( LMWH) had no net benefi t and that graduated compression stockings did not reduce the risk of DVT. The CLOTS 3 trial aimed to establish whether intermittent pneumatic compression (IPC) reduced the risk of deep vein thrombosis (DVT) in patients admitted to hospital after an acute stroke who were initially immobile. Before starting the trial, we searched for other trials that had addressed this question in stroke patients. We updated this search in March, 2013. We searched the Cochrane Stroke Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline (1966 to March 2013), Embase (1980 to March, 2013), CINAHL (1982 to March, 2013) and The British Nursing Index (1985 to March, 2013) using the search terms listed in the appendix. We screened reference lists of all relevant papers, searched ongoing trials registers (March, 2013), and contacted experts in the fi eld. We included unconfounded randomised controlled trials comparing IPC for reducing the risk of DVT with control and in which prophylaxis was started within 7 days of the onset of stroke.
We identifi ed two small trials of IPC, one including 151 patients with haemorrhagic stroke and the other 26 patients with unspecifi ed stroke. When the results of CLOTS 3 are meta-analysed with the results of the two other trials, the estimates of treatment eff ects are an OR of 0·66 (95% CI 0·52-0·84) for proximal DVT, an OR of 0·71 (0·59-0·85) for any DVT, and an OR of 0·81 (0·65-1·01) for deaths by the end of the treatment period. The two other trials did not report any symptomatic DVTs or pulmonary emboli.
The overall rate of proximal DVT in the CLOTS 3 trial was 10·3% (296 of 2876 patients), almost identical to that reported in CLOTS 1 3 (thigh-length graduated compression stockings vs none; 10·3% [259 of 2518 patients]), but higher than that in CLOTS 2 4 (thigh-length graduated compression stockings vs below-knee; 7·6% [236 of 3114 patients]). The death rates at 30 days were 12·0% (345 of 2876 patients) in CLOTS 3, 9·2% (232 of 2518 patients) in CLOTS 2, 4 and 11·4% (356 of 3114 patients) in CLOTS 1. 3 In CLOTS 3, 62·2% (1790 of 2876) of patients enrolled had a probability of a good outcome of 0-0·15 (ie, severe stroke; table 1), while the equivalent fi gures were 53·4% (1344 of 2518) in CLOTS 1 3 and 54·3% (1690 of 3114) in CLOTS 2. 4 In all three trials, early screening CDU was performed in about 91% of enrolled patients, whilst in CLOTS 3 the second CDU was done in 65·7% (1890 of 2876) compared with only 57·8% (1456 of 2518) in CLOTS 1 3 and 41·2% (1282 of 3114) in CLOTS 2. 4 Since patients in CLOTS 3 had more severe strokes, and were more intensively screened for DVT, one would have expected higher DVT and death rate-however this may in part have been off set by 50% of the patients in CLOTS 3 receiving eff ective prophylaxis for venous thromboembolism with IPC.
Interpretation
The CLOTS 3 data provide robust evidence for the eff ectiveness of IPC in the prevention of DVT and it possibly improves survival in patients who are initially immobile (ie, cannot walk to the toilet without the help of another person) after being hospitalised with acute stroke.
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